Intra-Cellular Therapies (ITCI) Competitors $83.45 -0.69 (-0.82%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ITCI vs. BNTX, TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, and CTLTShould you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Intra-Cellular Therapies vs. BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Intra-Cellular Therapies (NASDAQ:ITCI) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is ITCI or BNTX more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% BioNTech -15.16%-2.35%-2.05% Does the media refer more to ITCI or BNTX? In the previous week, BioNTech had 5 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 9 mentions for BioNTech and 4 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.96 beat BioNTech's score of 0.66 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ITCI or BNTX? Intra-Cellular Therapies currently has a consensus price target of $97.23, indicating a potential upside of 16.51%. BioNTech has a consensus price target of $140.76, indicating a potential upside of 24.48%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85BioNTech 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.82 Does the MarketBeat Community prefer ITCI or BNTX? Intra-Cellular Therapies received 382 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 67.84% of users gave Intra-Cellular Therapies an outperform vote while only 45.87% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% BioNTechOutperform Votes13945.87% Underperform Votes16454.13% Which has more volatility & risk, ITCI or BNTX? Intra-Cellular Therapies has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Do institutionals & insiders believe in ITCI or BNTX? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable earnings and valuation, ITCI or BNTX? BioNTech has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$612.78M14.44-$139.67M-$0.87-95.92BioNTech$3.04B8.84$1.01B-$2.10-53.85 SummaryBioNTech beats Intra-Cellular Therapies on 10 of the 19 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITCI vs. The Competition Export to ExcelMetricIntra-Cellular TherapiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.85B$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-95.9210.5990.1317.20Price / Sales14.44196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book13.575.094.784.78Net Income-$139.67M$151.83M$120.31M$225.60M7 Day Performance0.51%-2.14%-1.92%-1.23%1 Month Performance-2.61%-4.56%13.65%0.46%1 Year Performance18.62%8.87%28.34%15.24% Intra-Cellular Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITCIIntra-Cellular Therapies4.0543 of 5 stars$83.45-0.8%$97.23+16.5%+25.1%$8.85B$612.78M-95.92560BNTXBioNTech2.0872 of 5 stars$114.07-5.2%$140.76+23.4%+9.2%$27.12B$3.04B-56.016,133TEVATeva Pharmaceutical Industries1.8723 of 5 stars$16.66+1.0%$19.67+18.0%+108.5%$18.87B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6104 of 5 stars$176.80-1.4%$253.69+43.5%-0.3%$17.23B$2.46B-21.7710,600MRNAModerna4.2742 of 5 stars$41.65-0.4%$79.50+90.9%-56.8%$16.03B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0503 of 5 stars$12.69+0.5%$13.67+7.7%+17.6%$15.15B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2734 of 5 stars$18.71+4.9%$33.33+78.2%+650.8%$13.80B$700,000.00-63.68105News CoverageGap DownGMABGenmab A/S4.2395 of 5 stars$20.14-0.1%$45.20+124.4%-34.6%$13.33B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8134 of 5 stars$14.77+2.1%$17.00+15.1%+15.1%$12.33B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8162 of 5 stars$126.12+1.9%$178.71+41.7%+31.1%$12.05B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7663 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading Volume Related Companies and Tools Related Companies BNTX Alternatives TEVA Alternatives BGNE Alternatives MRNA Alternatives VTRS Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives SRPT Alternatives CTLT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ITCI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITCI Stock Alerts